July 29, 2020 -- Constant Therapeutics will begin a phase II clinical trial of the peptide drug TXA127 at Columbia University Irving Medical Center in New York City for the treatment of COVID-19.
The double-blind, placebo-controlled trial will enroll approximately 100 patients with COVID-19 who require oxygen but are not in the intensive care unit. The company will study the incidence of renal failure and respiratory failure in participants.
TXA127 is a Mas receptor agonist that has the potential to reduce inflammation and prevent lung injury while stabilizing endothelial and epithelial barriers and reducing fibrosis.
The company previously announced that it plans to conduct additional phase II trials of the drug in Boston, MA, Bologna, Italy, and in Israel.